Scientists pinpointed 16 new genetic variants in people who developed severe COVID-19 in a large study published on March 7 that could help researchers develop treatments for very sick patients.

San Francisco-based biotech company Alumis, formerly Esker Therapeutics, closed on a $200 million Series B financing round.

Bristol Myers Squibb announced positive data from POETYK PSO-2, the second Phase III trial of deucravacitinib for moderate to severe plaque psoriasis, evaluated against placebo and Amgen’s Otezla (apremilast).

A recent study shows that Bristol Myers Squibb’s oral tyrosine kinase 2 (TYK2) inhibitor deucravacitinib was associated with noticeable improvements in signs and symptoms of psoriatic arthritis compared with placebo.

Bristol Myers Squibb’s experimental psoriasis drug deucravacitinib (BMS-986165) beat out Amgen’s Otezla (apremilast) in the POETYK PSO-1 Phase III clinical trial.

Exelixis’s Cabometyx (cabozantinib) hit key endpoints of overall survival in its Phase III liver cancer trial.

Celgene entered into a partnership to take on autoimmune diseases with two of New Jersey-based Nimbus Therapeutics’ preclinical therapeutics.